<scp>CD</scp>180 overexpression in follicular lymphoma is restricted to the lymph node compartment

Mestrallet, Fanélie; Sujobert, Pierre; Sarkozy, Clémentine; Traverse-Gléhen, Alexandra; Callet‐Bauchu, Evelyne; Magaud, Jean‐Pierre; Salles, Gilles; Baseggio, Lucile

doi:10.1002/cyto.b.21331

Cited by 11 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, many studies have reported that the significantly different expression of CD43 in CLL and other mature B‐cell neoplasms could improve the differential diagnosis 13,19,20,35 . CD180 also had differential expression among mature B‐cell neoplasms and was identified to have a sensitivity of 77% and a specificity of 92% for the diagnosis of MZL 24‐26 . In CLL, CD180 could extend the proliferation and survival of B cells, 36 and was involved in susceptibility to fludarabine 37 .…”

Section: Discussionmentioning

confidence: 99%

“… 23 , 24 The differential expression of CD180 among chronic B‐cells lymphoproliferative diseases has been reported. 24 , 25 , 26 This study aimed to investigate the immunophenotyping data of patients with mature B‐cell malignancies, and whether a new combined score including CD43 and CD180 could improve the diagnostic value of CLL versus non‐CLL, particularly in CLL with CD5 or CD23 negativity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia

Tong

Huang

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

Moreau score has been used to differentiate chronic lymphocytic leukemia (CLL) from other mature B‐cell neoplasms. However, it showed limitations in Asian patients. Therefore, we conducted a new score system replacing CD5 and CD23 with CD43 and CD180 to evaluate its diagnostic value of CLL. 237 untreated samples diagnosed with mature B‐cell neoplasms were collected and were randomly divided into an exploratory and a validation cohort by a 2:1 ratio. The expression of CD5, CD19, CD20, CD23, CD43, CD79b, CD180, CD200, FMC7, and surface immunoglobulin (SmIg) were analyzed among all the samples. A proposed score was developed based on the logistic regression model. The sensitivity and specificity of the proposed score were calculated by ROC curves. CD43/CD180, CD200, FMC7, and CD79b were included in our new CLL score, which showed a sensitivity of 91.8% and a specificity of 83.1%. These results were confirmed in a validation cohort with a sensitivity of 90.5% (p = 0.808) and a specificity of 79.5% (p = 0.639). In CD5 negative or CD23 negative CLL group, the new CLL score displayed improved sensitivity of 79.4% compared to Moreau score and CLLflow score (41.2% and 47.1%, respectively). In atypical CLL group, the new CLL score showed improved sensitivity of 84.2% compared to Moreau score and CLLflow score (61.4% and 64.9%, respectively). This proposed atypical CLL score helped to offer an accurate differentiation of CLL from non‐CLL together with morphological and molecular methods, particularly in Chinese patients with atypical immunophenotype.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia

Tong

Huang

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Having a vaccine platform that is capable of acting on the first newly formed B cells to emerge from the BM may be a successful strategy for protecting these immunocompromised individuals. A potential concern of CD180 targeting transitional B cells is the activation of bystander B cells (61)(62)(63). Although in the B1-8 hi system this bystander activation was limited (Fig.…”

Section: Discussionmentioning

confidence: 99%

Targeting Antigens to CD180 but Not CD40 Programs Immature and Mature B Cell Subsets to Become Efficient APCs

Roe

Shu

Draves

et al. 2019

The Journal of Immunology

View full text Add to dashboard Cite

Targeting Ags to the CD180 receptor activates both B cells and dendritic cells (DCs) to become potent APCs. After inoculating mice with Ag conjugated to an anti-CD180 Ab, B cell receptors were rapidly internalized. Remarkably, all B cell subsets, including even transitional 1 B cells, were programed to process, present Ag, and stimulate Ag-specific CD4 + T cells. Within 24-48 hours, Ag-specific B cells were detectable at T-B borders in the spleen; there, they proliferated in a T cell-dependent manner and induced the maturation of T follicular helper (T FH) cells. Remarkably, immature B cells were sufficient for the maturation of T FH cells after CD180 targeting: T FH cells were induced in BAFFR 2/2 mice (with only transitional 1 B cells) and not in mMT mice (lacking all B cells) following CD180 targeting. Unlike CD180 targeting, CD40 targeting only induced DCs but not B cells to become APCs and thus failed to efficiently induce T FH cell maturation, resulting in slower and lower-affinity IgG Ab responses. CD180 targeting induces a unique program in Ag-specific B cells and to our knowledge, is a novel strategy to induce Ag presentation in both DCs and B cells, especially immature B cells and thus has the potential to produce a broad range of Ab specificities. This study highlights the ability of immature B cells to present Ag to and induce the maturation of cognate T FH cells, providing insights toward vaccination of mature B cell-deficient individuals and implications in treating autoimmune disorders.

show abstract

“…This issue contains two manuscripts examining CD180 in B cell lymphomas (9,10). The utility of CD180 is based just not on the presence or absence of this antigen, but also on the intensity of staining, similar to how CD200 is evaluated in B cell neoplasms (11).…”

Section: Cd180 In B Cell Lymphomasmentioning

confidence: 99%

“…They also show that CD180 is highly expressed on hairy cell leukemias (HCL). Also in this issue, Mestrallet and coworkers (10) examine CD180 expression in both the peripheral blood and lymph nodes from patients with follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), mantel cell lymphoma (MCL), and marginal zone lymphoma (MZL), and well as from non-tumor-bearing controls. These authors again confirm the association of high levels of CD180 expression in the peripheral blood with MZL; however they extend these findings with the observation that CD180 expression is also high in the lymph nodes, but not peripheral blood, in cases of follicular lymphoma.…”

Section: Cd180 In B Cell Lymphomasmentioning

confidence: 99%

Issue Highlights – September 2016

McCoy¹

2016

Cytometry Part B Clinical

View full text Add to dashboard Cite

This issue of Cytometry Part B: Clinical Cytometry contains nine articles, eight of which examine topics related to hematopoietic neoplasms. NON-NEOPLASTIC T CELLS IN LYMPHOMASAND LEUKEMIAS Three of these manuscripts do not directly study neoplastic cells in patient cohorts but rather present studies of non-neoplastic T cell populations found in patients with lymphoma or leukemia. In one study, Hunt and colleagues (1) describe the use of internal non-neoplastic T cells as controls in the evaluation of T cell neoplasms. The staining patterns of the normal T cells can function as a process control, assuring that all steps of sample preparation, staining, and analysis were performed correctly. Furthermore, with standardization of staining and analysis, these internal T cell can also be used as controls for the assessment of staining intensities in presumptively abnormal T cells. Caveats to this approach included the paucity of some T cell subpopulations in all patients and instrument to instrument variability in measuring staining intensities, highlighting the need for standardization in both staining and instrument set up.In a second study Gunduz et al (2) examined peripheral blood T regulatory (Treg) cells in newly diagnosed lymphoma patients (both Hodgkin and non-Hodgkin). Increasingly, immune regulators and responses in patients with neoplasms are of interest, as these may tell if and how the abnormal cells are escaping immune surveillance. Recent examples include a study of natural killer (NK) cells and NK-like T cell populations in acute myeloid leukemia (3) and a study of memory and na€ ıve T cells in chronic lymphocytic leukemia (4). Several additional studies have examined Treg cells in hematologic neoplasms (5,6). In the current study Gunduz and coworkers look at Tregs (CD41CD25highFoxP31) in the peripheral blood of cohorts of Hodgkin lymphoma (HL) patients, non-Hodgkin lymphoma (NHL) patients, and healthy subjects and attempt to correlate the number of Tregs with a variety of patient characteristics. While a number of correlations were observed with prognostic factors in both HL and NHL patients, the only correlation observed with survival was in NHL patients where the number of Tregs inversely correlated with overall survival. These results, while preliminary, suggest that immune parameters might be feasible for use as prognostic markers, although much work remains to be done to precise how and why this can be done.In related work, Wu and associates (7) queried whether reactive T cells in lymphocyte rich classical HL, nodular HL and T cell/histiocyte rich large B cell lymphoma could provide information of diagnostic utility. This study builds upon and extends the work of Seegmiller et al in which CD7 overexpressing T cells were identified in infiltrates of classical HL (8). In the current study a variety of phenotypes (T cells, CD4, CD8, B cell, NK cells dual positive CD41CD81, CD7 bright T cells) were examined in the infiltrates of these lymphomas and attempts were made to correlate these with the diag...

show abstract

CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment

Abstract: These FCM data confirm the usefulness of CD180 in the accurate diagnosis of LPDs and emphasize the need to interpret this marker according to the origin of the sample. © 2015 Clinical Cytometry Society.

Cited by 11 publications

References 20 publications

A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia

A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia

Targeting Antigens to CD180 but Not CD40 Programs Immature and Mature B Cell Subsets to Become Efficient APCs

Issue Highlights – September 2016

Contact Info

Product

Resources

About